Rossari Biotech Ltd — earnings calls

Rossari Biotech reported consolidated revenue of Rs. 697.2 crore in Q1 FY27, up 28% YoY, along with its highest ever quarterly EBITDA of Rs. 80.6 crore, up 18.7% YoY, though EBITDA margin declined to 11.6% from 12.5% a year earlier. Management attributed the margin pressure to the institutional and consumer business, raw material and freight volatility, and product mix, while noting that core B2B operations excluding these businesses delivered around 14% EBITDA margin. The company discussed ongoing initiatives including a new Thailand blending plant, a proposed Saudi Arabia project, a new Fibre Chemicals Division, and continued monetization of non-core assets such as the Andheri office.

Rossari Biotech reported Q4 FY26 revenue of Rs. 684.9 crore, up 18% YoY, and full-year FY26 revenue of Rs. 2,396.4 crore, up 15% YoY, with EBITDA margin for the year at 11.9% versus 12.7% in FY25. Management attributed margin pressure to raw material price increases in March and a challenging institutional and B2C business, while noting core B2B operations delivered a 14% EBITDA margin. The company also disclosed a rephasing of its previously announced Rs. 192 crore capex plan across Rossari, Unitop and Tristar in light of evolving business and market conditions.